Ectomesenchymal Chondromyxoid Tumor of the Oral Cavity: A Report of 5 New Cases with Comprehensive Review of the Literature and Clinicohistopathological Features

Published:December 20, 2022DOI:

      Statement of Clinical Relevance

      • ECT is an uncommon tumor with a wide spectrum of histopathologic and immunohistochemical features. A thorough review of its characteristics is beneficial to the treating clinicians and pathologists as they diagnose and manage patients with this rare neoplasm.



      : Ectomesenchymal chondromyxoid tumor (ECT) is an uncommon soft tissue tumor with an enigmatic histogenesis and striking predilection for the tongue. We present 5 new cases and review the literature.

      Study Design

      : We performed a retrospective search for ECTs within the University of Kentucky Oral Pathology Biopsy Service and the published literature.


      : Five new cases from the biopsy archives and 103 well-documented ECT cases from the literature were compiled and reviewed. 89.8% of ECT are found on the anterior/dorsal/lateral/unspecified tongue, while 4.6% are on the posterior/base of tongue. Six extralingual cases are reported. The age ranges from 2.3-78 years with an average of 40. Most ECT react with GFAP (92.8%) and S-100 protein (91.3%). 21/23 cases demonstrate a RREB1::MKL2 fusion, while EWSR1 gene mutations are identified in 4 cases.


      : Most ECT are readily diagnosed on routine histopathology in combination with tumor site, immunohistochemical findings, and molecular findings; however, a subset share overlapping features with myoepithelioma of soft parts. As further molecular analysis is performed on this tumor, we may find that a subset of previously diagnosed ECT relate to or represent myoepithelioma or conversely fall under the spectrum of the pluripotent ECT.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'